Article reviewed by: Pankaj Rajvanshi, MD, FAASLD, DABOM Dr
The compound achieved nearly 100% of the GLP-1 maximal response, indicating full agonistic behavior in terms of efficacy
This is thanks to unique integrations with LillyDirect and NovoCare
If dietary measures prove insufficient, speak with your GP about appropriate laxatives
Its dual mechanism of action targets the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which are crucial for regulating insulin secretion, improving insulin sensitivity, and reducing glucagon levels
Both may be helpful for the right patient and inappropriate for another